Ridglan Farms, a Dane County, Wisconsin beagle breeding and research facility that supplied dogs to laboratories for decades, has permanently shut down following a negotiated transfer of its remaining animals to rescue organizations, according to The Guardian.

Approximately 1,500 beagles were released as part of the closure deal. Big Dog Ranch Rescue — a cage-free, no-kill organization — secured hundreds of those animals. The Center for a Humane Economy was involved in brokering the negotiation that made the transfer possible.

Lauree Simmons, CEO, President, and Founder of Big Dog Ranch Rescue, was a central figure on the rescue side of the arrangement.

Ridglan Farms occupied a well-documented position in the U.S. preclinical research supply chain. Beagles are the default canine model in toxicology and pharmacokinetics studies — their docile temperament and size make them practical for laboratory protocols — and purpose-bred suppliers like Ridglan provided a regulated, traceable pipeline to contract research organizations and pharmaceutical companies for decades. The facility's closure removes one of those nodes from a supply chain that has already been under sustained regulatory and advocacy pressure.

The Center for a Humane Economy has pursued similar negotiated closures at other Class B and purpose-bred dealer operations in recent years, typically combining legal scrutiny, public campaigns, and direct engagement with facility operators. A negotiated exit — in which the operator transfers animals rather than facing protracted enforcement proceedings — has become the preferred resolution mechanism for advocacy groups seeking both speed and animal welfare outcomes. It sidesteps the slower machinery of USDA enforcement while giving operators a defined path out.

What the Ridglan closure does not immediately resolve is downstream research demand. Laboratories relying on purpose-bred beagles will source from alternative suppliers; the market does not disappear with a single facility. The more consequential long-term question is whether non-animal testing methodologies — organ-on-a-chip platforms, advanced in-vitro assays, computational toxicology — reach regulatory acceptance fast enough to compress that demand structurally. The FDA Modernization Act 2.0, signed into law in late 2022, removed the statutory requirement for animal testing in drug development, giving agencies discretion to accept alternatives. Uptake has been incremental.

For Big Dog Ranch Rescue, absorbing hundreds of purpose-bred beagles simultaneously is a significant operational undertaking. Purpose-bred research dogs often lack socialization to domestic environments, requiring structured behavioral rehabilitation before adoption placement. The logistics of transport, veterinary intake screening, and foster or adoption pipelines at that scale are non-trivial, even for an experienced no-kill organization.

The negotiated closure model, whatever its limits, now has another case study attached to it.